Physician profile
Brooke Tuttle
NPI 1871014159
$3,188.29
in general payments reported to CMS, 2019-2025
30 companies · $968 in 2025
The $968 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $222 · 2022: $459 · 2023: $688 · 2024: $851 · 2025: $968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,507.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,104.48 | 2021-2025 | |
| Novo Nordisk INC | $249.61 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Otsuka America Pharmaceutical, INC. | $217.33 | 2022-2025 | Rexulti |
| Pfizer INC. | $189.90 | 2023-2025 | |
| Astellas Pharma US INC | $176.35 | 2023-2025 | Veozah |
| Lilly USA, LLC | $150.55 | 2021-2025 | Mounjaro |
| Biohaven Pharmaceutical Holding Company LTD. | $136.92 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $121.63 | 2024-2025 | Farxiga, Breztri, Airsupra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $90.44 | 2025 | Caplyta |
| Mylan Specialty L.P. | $89.90 | 2023-2024 | Yupelri |
| Medtronic, INC. | $68.12 | 2024-2025 | Intellis Adaptivestim, Minimed 780g |
| Exact Sciences Corporation | $65.18 | 2023-2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $61.86 | 2025 | Symbravo |
| Organon LLC | $60.81 | 2022-2025 | Nexplanon |
| Boston Scientific Corporation | $55.62 | 2022-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $43.38 | 2021 | |
| Daiichi Sankyo INC. | $42.57 | 2021 | |
| Lundbeck LLC | $35.71 | 2025 | Rexulti |
| Inspire Medical Systems, INC. | $33.34 | 2024-2025 | Inspire |
| Idorsia Pharmaceuticals US INC | $30.55 | 2023 | Quviviq |
| Amgen INC. | $21.52 | 2025 | Evenity |
| Cranial Technologies, INC | $19.25 | 2025 | Doc Band |
| Phadia US INC. | $17.90 | 2023 | Immunocap |
| Almatica Pharma LLC | $17.60 | 2023 | Loreev Xr |
| Corium, LLC | $15.95 | 2025 | Azstarys |
| Sunovion Pharmaceuticals INC. | $15.66 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.17 | 2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $14.61 | 2023 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $13.68 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $12.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Tuttle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.